Pomalidomide and Low-Dose Dexamethasone for Relapsed/Refractory MM


Pomalidomide and Low-Dose Dexamethasone for Relapsed/Refractory MM
Slides from presentations at ASH 2013 and transcribed comments from a recent interview with Rafael Fonseca, MD (2/14/14)
Dimopoulos MA et al. Final analysis, cytogenetics, long-term treatment, and long-term survival in MM-003, a Phase 3 study comparing pomalidomide + low-dose dexamethasone (POM + LoDEX) vs high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM). Proc ASH 2013;Abstract 408.

Leleu X et al. Pomalidomide plus low-dose dexamethasone in relapsed or refractory multiple myeloma (RRMM) with deletion (del)17p and/or translocation t(4;14). Proc ASH 2013;Abstract 689.

Dr Fonseca is Getz Family Professor of Cancer and Chair of the Department of Internal Medicine at the Mayo Clinic Arizona in Scottsdale, Arizona.